Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2237  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (99 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References

 Article Access Statistics
    Viewed6732    
    Printed114    
    Emailed1    
    PDF Downloaded1123    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 


 
INVITED COMMENTARIES
Year : 2007  |  Volume : 55  |  Issue : 1  |  Page : 8-9

Thrombolytic treatment in acute cerebral infarction


Cerebrovascular Division, Department of Neurology, Hospital Universitari del Sagrat Cor, Universitat de Barcelona, Viladomat 288, E-08029 Barcelona, Spain

Correspondence Address:
Adria Arboix
Cerebrovascular Division, Department of Neurology, Hospital Universitari del Sagrat Cor, Universitat de Barcelona, Viladomat 288, E-08029 Barcelona
Spain
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.30418

Rights and Permissions



How to cite this article:
Arboix A. Thrombolytic treatment in acute cerebral infarction. Neurol India 2007;55:8-9

How to cite this URL:
Arboix A. Thrombolytic treatment in acute cerebral infarction. Neurol India [serial online] 2007 [cited 2020 Jan 21];55:8-9. Available from: http://www.neurologyindia.com/text.asp?2007/55/1/8/30418


"Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: Efficacy and safety profile of 54 patients at a tertiary referral center in a developing country" in this issue of Neurology India have provided further evidence of the high benefits of timely thrombolytic therapy in acute cerebral infarction.[2] In the majority of cases, ischemic stroke is caused by an embolus occluding a cerebral artery and early thrombolytic treatment allows re-establishment of bloodflow before a definite and irreversible brain infarction develops. Meta-analysis of studies of thrombolytic therapy confirms that in patients treated within the first 3h after stroke onset, thrombolysis is more effective than placebo in the reduction of mortality rate or functional dependence. The high benefit of thrombolytic therapy with intravenous t-PA is related to the prevention of death or functional dependence in one of each seven patients treated.[3] Recently, it has been shown that benefits of intravenous t-PA includes not only the use of this agent during the first 3h window after the onset of ischemic stroke, but also up to 4.5h after the onset of symptoms.[4] In daily practice, however, thrombolysis is used in less than 4% of patients with cerebral infarction mostly due to the fact that patients continue to arrive too late to hospitals, so that the majority of patients are attended out of the range of the 3h window for intravenous thrombolytic therapy and out of the first 6h recommended for the use of intra-arterial thrombolysis.[5] Despite the high benefits of t-PA administration, arterial re-vascularization is not achieved in 30-40% of patients and potentially life-threatening hemorrhagic complications occur in 5-10% of patients.[3] The SIST-MOST study is an observational pharmacosurveillance study carried out in different countries of the European Union, the objective of which is to assess the results of thrombolytic treatment with t-PA within the first 3h after stroke onset in patients with well-defined inclusion criteria and attended in qualified centers, although without previous experience in the use of this treatment modality, with an expected follow-up of three years. This study will answer whether satisfactory results obtained in clinical trials are reproducible to clinical conditions of daily practice in medical centers without experience in the use of thrombolytic therapy.[6]

Future challenges of thrombolytic therapy include a significant increase in the frequency of administration and use of this therapy, to increase arterial re-vascularization rates, to decrease the occurrence of post-treatment bleeding and to extend the therapeutic window for the inclusion of candidates to this treatment modality. In this respect, healthcare education continues to be an essential step to achieve the first goal. The administration of t-PA together with the use of ultrasound (known as sonothrombolysis) has shown to increase the frequency of arterial re-permeabilization in preliminary studies. In addition, the therapeutic usefulness of third-generation thrombolytic drugs (tenecteplase, reteplase, lanoteplase, pamiteplase and staphylokinase) is potentially greater because of a higher resistance than t-PA to neutralization by t-PA endogenous inhibitors or a longer mean half life. Another therapeutic approach would be the concomitant use of conventional thrombolytic therapy and neuroprotector drugs with the aim of maximal preservation of the ischemic shadow territory limiting the extension of the cerebral infarcted area. The use of diffusion-perfusion MRI is a further potential alternative, which may allow the administration of thrombolysis treatment independently of the temporal window in cases in which potentially recoverable cerebral tissue could be demonstrated. This would occur when cerebral ischemia in perfusion sequences is significantly greater than cerebral infarction visualized in the diffusion sequences (the so-called "mismatch" phenomenon). Mechanical disruption of thrombi by embolectomy is another potentially interesting possibility in non-responders to intravenous or intra-arterial t-PA administration. Finally, the usefulness of plasma biomarkers related to the efficacy and safety of thrombolytic treatment and that would alert to the risk of hemorrhagic transformation[4],[1] will be another future challenge that will allow optimization and individualization of thrombolytic therapy in the patient suffering from an acute cerebral infarction.

 
  References Top

1.Padma MV, Singh MB, Bhatia R, Srivastava A, Tripathi M, Shukla G, et al . Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: Efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol India 2007;55:46-9.  Back to cited text no. 1    
2.Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolisis for acute ischaemic stroke. Cochrane Database Syst Rev 2003;3:CD000213.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Davalos A. Thrombolisis in acute ischemic stroke: Successes, failures and new hopesw. Cerebrovasc Dis 2005;20:135-9.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Arboix A. Importance of the first 6 hours in acute cerebral ischemia. Conclusions. Present and Future (article in Spanish). Neurol Supl 2005;1:80-2.  Back to cited text no. 4    
5.SIST-MOST. Available from: http://acutestroke.org/.  Back to cited text no. 5    
6.Rubiera M, Ribo M, Delgado-Mederos R, Santamarina E, Delgado P, Montaner J, et al . Tandem internal carotid artery/middle cerebral artery occlusion. An independent predictor of poor outcome alter systemic trombolysis. Stroke 2006;37:2301-5.  Back to cited text no. 6    



This article has been cited by
1 Local mild hypothermia with thrombolysis for acute ischemic stroke within a 6-h window
Min Bi, Qilin Ma, Shiyang Zhang, Jianpeng Li, Yidan Zhang, Longting Lin, Suijun Tong, Desheng Wang
Clinical Neurology and Neurosurgery. 2011;
[VIEW] | [DOI]



 

Top
Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow